Centre Antoine Lacassagne, Université Cote d’Azur, Nice France reported on the TAXOMET trial results. They reported to ASCO that metformin, when added to docetaxel, has no impact on outcomes among patients with metastatic castration-resistant prostate cancer.
The first clinical trial to test the question of whether metformin can make a difference in outcome, the investigators noted that the drug fails to reduce prostate-specific antigen (PSA) levels any better than docetaxel along. Select the link to EurekAlert! for more details.
Pujalte Martin, MDSource: Physicians weekly